ARTG Entry Transfer and Sponsor Change Procedures

1. Key takeaways

Transfers of ARTG entries follow a “deemed successor plus notification” model, not an approval-based model. Under section 10F(5)(a) of the Therapeutic Goods Regulations 1990, where a business or interest in a business is transferred and the transfer of the ARTG entry is agreed, the transferee is deemed to be, from that day, the person in whose name the device is entered — obligations transfer immediately, even before TGA has received any notification. The 3 months period is a notification deadline, not a condition of effectiveness.

• The transferee bears reporting, record-keeping and annual charge duties from the transfer day itself.
• The gap between signing and notification is a period of transferred liability with an unupdated register.
• Outstanding annual charge debt blocks completion of a transfer.
• The transfer form cannot be lodged without the consent of the current sponsor.
• Death, bankruptcy and liquidation have their own succession rules with the same 3 months notice duty.

The practical reading is that the transaction documents carry the real regulatory weight. The register follows the contract, not the other way around, so the moment of signing is the moment of exposure, and the notification to TGA is an administrative finishing step rather than a protective one.

2. Legal basis

The transfer mechanism sits on an authorising provision in the Act and an operating provision in the regulations, with TGA practice adding three operational constraints.

1. Authorising provision: Therapeutic Goods Act 1989 (Act No. 21, 1990), section 63(2)(f) — authorises the regulations to make provision about transfers of entries in the register.
2. Transfer provisions: Therapeutic Goods Regulations 1990 (F1996B00406), section 10F; change of device name in section 10FA.
3. Core mechanism: section 10F(5)(a) — where the business or part of the business relating to a device is transferred or assigned, and the transfer of the ARTG entry is agreed, the transferee is deemed to be the person in whose name the device is entered from the day of the transfer; section 10F(5)(b) — written notice must be given within 3 months (this paragraph was inserted by F2009L01826).
4. Special situations: sections 10F(2)(3)(4) — on death the legal representative of the estate, on bankruptcy the trustee in bankruptcy, and on liquidation the liquidator succeed to the entry, and must notify within 3 months.
5. Register update: section 10F(7) — the Secretary must amend the register accordingly and issue a new certificate.
6. TGA operational constraints (TGA, Changing the sponsor of a therapeutic good): obligations transfer immediately upon the event, even if TGA has not yet been notified; a transfer cannot be completed while annual charge debt is outstanding; the transfer form must not be lodged without the consent of the current sponsor.

3. Expert insights

Insight 1: the risk window opens on the day of signing. Many companies assume that the transfer happens only once TGA approves it. In reality the transferee is deemed the registered person from the transfer day, and reporting, record-keeping and annual charge duties transfer with that status. The period between the signing day and the notification day is a gap in which liability has already moved but the system has not been updated. During that gap the transferee should already operate the adverse event channels, the distribution record system and the annual charge account, because a reportable event does not wait for the register to catch up.

Insight 2: annual charge debt can directly block the transfer. TGA states expressly that a transfer cannot be completed while annual charges are outstanding. Financial due diligence before a transfer must therefore include a check of annual charge payment status; otherwise the transaction cannot close. This also changes the negotiation: the annual charge ledger is not a bookkeeping detail but a closing condition, and any disputed invoice should be settled or documented before the transfer form is lodged.

Insight 3: the manufacturer has no standing to initiate a transfer. The transfer requires the consent of the current sponsor. A contractual clause allowing the manufacturer to replace the sponsor unilaterally cannot be executed at the level of the Australian register. Manufacturers should therefore secure sponsor-replacement leverage commercially — for example through service levels and exit rights in the supply agreement — rather than relying on a clause the register will not recognise.

Finally, note the interaction with certificates. Under section 10F(7) the Secretary amends the register and issues a new certificate once notified, so the transferee’s evidence pack for distributors and importers should anticipate a change of certificate detail. Customs brokers, major customers and freight forwarders who match invoices against certificate names should be told about the transition before it happens, to avoid shipments being questioned during the update window.

Above all, the deemed-succession rule means the transfer day should appear in both parties’ compliance calendars, with a standing item to confirm on that day that reporting channels, record custody and the annual charge account are either transferred or formally shared. Treatments that wait for the new certificate leave exactly the gap this article warns about.

4. Practical recommendations

• State the “deemed succession day” expressly in the transaction documents, and have the transferee take over reporting, record-keeping and annual charge duties from that day.
• Check annual charge payment status before closing; where debt exists, pay it off before lodging the transfer form.
• Start preparing the notification on the transfer day itself, so that written notice is completed within 3 months and proof of delivery is retained.
• Apply sections 10F(2)(3)(4) in death, bankruptcy and liquidation scenarios, with the corresponding representative performing the notification duty.

5. Verification checklist

• □ The deemed succession day is stated in the transaction documents
• □ Annual charge status was checked before closing, with no outstanding debt
• □ Consent of the current sponsor has been obtained
• □ Written notice was completed within 3 months and proof of delivery retained
• □ The transferee has taken over reporting and record-keeping duties from the transfer day

Regulatory information verified as of 29 October 2026

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Australian market. Our team coordinates Australian sponsor arrangements, ARTG annual charges, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com